

Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia

Submission date 21/10/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 21/10/2010	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 20/05/2021	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-vaccine-prevent-infections-children-acute-lymphoblastic-leukaemia>

Contact information

Type(s)

Scientific

Contact name

Dr Juliet Gray

Contact details

Southampton University Hospitals NHS Trust

Tremona Road

Southampton

United Kingdom

SO16 6YD

-

jcgray@soton.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2009-011587-11

Protocol serial number

8541

Study information

Scientific Title

Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia: a multicentre non-randomised interventional treatment trial

Acronym

PCV (Pneumococcal Conjugate Vaccine)

Study objectives

The main aim of this study is to produce evidence on which to base a vaccination guideline that will reduce the incidence of pneumococcal infection in children with acute leukoblastic leukaemia (ALL). This will be achieved by examining the efficacy of 13 valent conjugate pneumococcal vaccination (13vPCV) immunisation in this population. Our hypothesis is that 13vPCV will be sufficiently immunogenic to generate protective anti-pneumococcal immunity in children with ALL whilst they are receiving maintenance therapy and are most at risk of infection. However, it is possible that vaccination of children during treatment will not be effective due to the immunosuppressive effects of chemotherapy. Therefore vaccination with 13vPCV will also be tested in children at the end of their treatment and 6 months after completion of treatment. The earliest of these time points at which 13vPCV is found to achieve protective immunity will be adopted as the final recommendation for all children with ALL, in order to provide protection for as long as possible during and after their leukaemia therapy.

The main study question is therefore to identify the earliest time point that children with ALL can be effectively vaccinated with 13vPCV. In order to answer this, the study primary objective is to establish if 13vPCV can achieve protective levels of anti-pneumococcal antibodies:

1. During maintenance therapy
2. At the end of chemotherapy treatment
3. Six months after completion of treatment

Ethics approval required

Old ethics approval format

Ethics approval(s)

Southampton and South West Hampshire REC, Committee B, 11/02/2010, ref: 09/HO504/112

Study design

Multicentre non-randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Medicines for Children Research Network; Subtopic: All Diagnoses; Disease: All Diseases

Interventions

PCV-13 vaccine, single 0.5 ml dose of vaccine to each study participant.

Follow up length: 12 months

Study entry: other

Details: non-random allocation to treatment group, depending on current timepoint in ALL treatment

Intervention Type

Biological/Vaccine

Phase

Phase IV

Primary outcome(s)

Serum concentrations of IgG anti-capsular polysaccharide antibodies to pneumococcal serotypes, measured at 0, 1 and 12 months post-immunisation

Key secondary outcome(s)

1. Nasopharyngeal carriage of pneumococcal sp (including serotype and MLST), measured at 0 and 12 months post-immunisation
2. Opsonophagocytosis assay (OPA) against two pneumococcal serotypes, measured at 0, 1 and 12 months post-immunisation
3. Peripheral blood lymphocyte subsets, measured at 0 and 12 months post-immunisation
4. Serum concentrations of total immunoglobulins and IgG subclasses, measured at 0 and 12 months post-immunisation

Completion date

01/09/2012

Eligibility

Key inclusion criteria

1. Aged 2 to 18 years (inclusive), either sex
2. ALL confirmed by immunophenotyping at diagnosis
3. Currently receiving maintenance therapy as per UKALL 2003 treatment protocol, or treatment as per UKALL 2003 protocol completed within last 6 months
4. Informed consent of parent/guardian (+/- patient)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

2 years

Upper age limit

18 years

Sex

All

Total final enrolment

118

Key exclusion criteria

1. Concomitant acquired or congenital immunodeficiency
2. Concomitant immunosuppressive medication within previous 3 months, other than maintenance chemotherapy as per UKALL 2003 protocol
3. Previous severe or anaphylactic reaction to PCV
4. Previous severe or anaphylactic reaction to diphtheria toxoid
5. Children with a contraindication to receipt of any vaccine or a specific vaccine as stated in the Department of Health Green Book on immunisation (DOH, 2006)
6. Pregnancy or lactation

Routine immunisation with PCV7 prior to ALL therapy is not an exclusion criteria

Date of first enrolment

07/09/2010

Date of final enrolment

01/09/2012

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Southampton University Hospitals NHS Trust

Southampton

United Kingdom

SO16 6YD

Sponsor information**Organisation**

Southampton University Hospitals NHS Trust (UK)

ROR

<https://ror.org/0485axj58>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) Programme (ref: PB-PG-1207-15250)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	22/08/2020	18/06/2020	Yes	No
Results article	results	01/07/2020	18/06/2020	Yes	No
Basic results			20/05/2019	No	No
Plain English results			20/05/2021	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes